KR890006668A - 폴리펩티드 - Google Patents

폴리펩티드 Download PDF

Info

Publication number
KR890006668A
KR890006668A KR1019880014255A KR880014255A KR890006668A KR 890006668 A KR890006668 A KR 890006668A KR 1019880014255 A KR1019880014255 A KR 1019880014255A KR 880014255 A KR880014255 A KR 880014255A KR 890006668 A KR890006668 A KR 890006668A
Authority
KR
South Korea
Prior art keywords
polypeptide
hsa
nucleotide sequence
serum albumin
human serum
Prior art date
Application number
KR1019880014255A
Other languages
English (en)
Other versions
KR0153516B1 (ko
Inventor
제임스 발랑크 데이비드
힌클리프 에드웨드
존 제이쇼우 마이클
제임스 시니어 피터
Original Assignee
원본미기재
델타 바이오데트놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 델타 바이오데트놀로지 리미티드 filed Critical 원본미기재
Publication of KR890006668A publication Critical patent/KR890006668A/ko
Application granted granted Critical
Publication of KR0153516B1 publication Critical patent/KR0153516B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

내용 없음

Description

폴리펩티드
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 HSA(1-n)의 다른 C-말단이 있는 (박스로 표시됨) 천연 HSA의 가장 대표적인 것으로 현재 생각되어 지는 아미노산 서열을 도시한다.
제2도는 성숙 HSA를 코드하는 DNA서열을 도시한다.
제3도는 mHOB16의 제조과정의 다이아그램 예시도이다.
제4도는 pHOB31의 제조과정의 다이아그램 예시도이다.
제5도는 완전한 HSA를 뛰어넘는 HSA(1-389)의 증가된 수율을 나타내는 로케트 전기영동 사진도이다.
제6도는 pDBD3의 제조과정을 도시한다.
제7도는 pDBD4의 제조과정을 도시한다.
제8도는 빌리루빈의 HSA(1-387)에의 결합을 나타내는 빌리루빈 형광의 증가를 나타내는 그래프를 도시한다.
제9도는 주어진 단백질 농도에서의 콜로이드 삼투압의 그래프를 도시한다.

Claims (13)

  1. 아미노산 잔기 n까지 (그중 n은 369 내지 419이지만 387은 아님)의 성숙 사람 혈청 알부민의 N-말단 부분을 포함하는 폴리펩티드, 및 그의 변이체.
  2. 제1항에 있어서, 폴리펩티드는 HSA(1-373), HSA(1-388), HSA(1-389), HSA(1-390), 및 HSA(1-407)로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 폴리펩티드 및 그의 변이체.
  3. n이 387일 수 있는 것을 제외한 제1항 또는 제2항의 폴리펩티드를 포함하는 의약 조성물.
  4. 제3항에 있어서, 폴리펩티드는 HSA(1-387)또는 그의 변이체인 것을 특징으로 하는 조성물.
  5. 아미노 산 잔기 n까지(그중 n은 309 내지 419이다)의 성숙 사람 혈청 알부민의 N-말단부분을 포함하는 폴리펩티드, 및 그의 폴리펩티드 변이체를 코드화하는 뉴클레오티드 서열에 있어서, 뉴클레오티드 서열은 그의 3'끝에서 아미노산 잔기 n+1에서 585 까지의 성숙 사람 혈청 알부민의 C-말단 부분을 코드화하는 추가의 서열에 연결되지 않는 뉴클레오티드 서열.
  6. 제5항에 있어서, n이 387인 것을 특징으로 하는 뉴클레오티드 서열.
  7. HSA의 pro-, pre-, 또는 pre-pro-위치, 메티오닌 잔기, 또는 다른 리더 서열에 대응하는 펩티드를 코드화하는 추가의 뉴클레오티드 서열에 그의 5'끝에서 연결된 제5항 또는 제6항의 뉴클레오티드 서열.
  8. 선택된 숙주에서의 형질전환 및 발현에 적당한 발현 백터에 있어서, 벡터는 제6항 내지 제8항중 어느 하나의 뉴클레오티드 서열을 포함하고 상기 뉴클레오티드 서열은 DAN서열인 것을 특징으로 하는 발현 벡터.
  9. 제8항의 벡터로 형질전환된 숙주 유기체.
  10. 제9항에 있어서, 맥주 효모균인 것을 특징으로 하는 숙주 유기체.
  11. 제9항 또는 제10항의 숙주 미생물의 적당한 조건하의 배양액을 포함하는 포리펩티드의 제조 방법에 있어서, 상기 폴리펩티드는 상기 뉴클레오티드 서열에 의하여 코드화되는 것을 특징으로 하는 방법.
  12. n이 387일 수 있는 것을 제외한 제1항의 폴리텝티드를 포함하는 미생물 성장용 실험실 재지.
  13. 제12항에 있어서, n이 387인 것을 특징으로 하는 배지.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880014255A 1987-10-30 1988-10-31 폴리펩티드 KR0153516B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878725529A GB8725529D0 (en) 1987-10-30 1987-10-30 Polypeptides
GB8725529 1987-10-30

Publications (2)

Publication Number Publication Date
KR890006668A true KR890006668A (ko) 1989-06-15
KR0153516B1 KR0153516B1 (ko) 1998-10-15

Family

ID=10626211

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880014255A KR0153516B1 (ko) 1987-10-30 1988-10-31 폴리펩티드

Country Status (17)

Country Link
US (1) US5380712A (ko)
EP (1) EP0322094B1 (ko)
JP (1) JPH02194A (ko)
KR (1) KR0153516B1 (ko)
AT (1) ATE82858T1 (ko)
AU (1) AU619768B2 (ko)
CA (1) CA1341298C (ko)
DE (1) DE3876401T2 (ko)
DK (1) DK175046B1 (ko)
ES (1) ES2053758T3 (ko)
FI (1) FI101381B1 (ko)
GB (1) GB8725529D0 (ko)
GR (1) GR3007162T3 (ko)
HU (1) HU209145B (ko)
IE (1) IE61050B1 (ko)
IL (1) IL88223A (ko)
ZA (1) ZA888118B (ko)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
ATE92107T1 (de) * 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
GB8927480D0 (en) * 1989-12-05 1990-02-07 Delta Biotechnology Ltd Mutant fungal strain detection and new promoter
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5698517A (en) * 1994-03-21 1997-12-16 University Of Hawaii, Office Of Technology Transfer And Economic Development Thyroxin-binding HSA fragments
US5674842A (en) * 1994-10-26 1997-10-07 Health Research, Incorporated Growth inhibitory peptide
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
EP0947581A4 (en) * 1996-08-08 2004-07-28 Mitsubishi Pharma Corp CULTURAL MEDIUM AND ITS USE.
US6274305B1 (en) 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
EP1121425B1 (en) * 1998-10-13 2005-06-29 The University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP1276849A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
KR20030068536A (ko) * 2000-09-11 2003-08-21 다나-파버 캔서 인스티튜트 Ｍｕｃ1 세포외 도메인 및 이로부터 유래된 암 치료조성물과 방법
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
US20020110841A1 (en) * 2000-12-22 2002-08-15 KUFE Donald W. Regulation of cell growth by MUC1
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
CN105131104B (zh) 2001-10-10 2018-11-16 诺和诺德公司 肽的重构和糖缀合
NZ532027A (en) 2001-10-10 2008-09-26 Neose Technologies Inc Remodeling and glycoconjugation of peptides
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR20040089608A (ko) 2002-02-07 2004-10-21 델타 바이오테크놀로지 리미티드 Ｈｉｖ 억제 단백질
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
JP2006524036A (ja) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
WO2005042573A1 (en) * 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
US20070202134A1 (en) * 2004-02-23 2007-08-30 Kufe Donald W Muc1 Antagonist Enhancement of Death Receptor Ligand-Induced Apoptosis
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
US20060204512A1 (en) 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
KR20140077946A (ko) 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
EP2054437A2 (en) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
EP2615108B1 (en) 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
US7884184B2 (en) 2007-01-30 2011-02-08 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US20100183596A1 (en) 2007-04-12 2010-07-22 Hester Jeanette Bootsma Virulence Factors of Streptoccus Pnuemoniae
MX2009011109A (es) 2007-04-17 2009-12-01 Plant Res Int Bv Glicosilación tipo mamífera en plantas para la expresión de glicosil-transferasas no mamíferas.
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
KR20100018040A (ko) 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EP2930182A1 (en) 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
EP2174664A1 (en) 2008-10-07 2010-04-14 Stichting Katholieke Universiteit, more particularly the Radboud University Nijmegen Medical Centre New virulence factors of Streptococcus pneumoniae
IT1392551B1 (it) * 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
AU2009324037B2 (en) 2008-12-05 2015-07-30 Glaxo Group Limited Methods for selecting protease resistant polypeptides
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
WO2010094720A2 (en) 2009-02-19 2010-08-26 Glaxo Group Limited Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
MX2011011338A (es) 2009-04-27 2012-04-19 Novartis Ag Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
JP2012532619A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
ES2552177T3 (es) 2009-10-27 2015-11-26 Glaxo Group Limited Polipéptidos anti-TNFR1 estables, dominios variables de anticuerpos y antagonistas
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
CN105567699A (zh) 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 白蛋白变体
GB0919837D0 (en) 2009-11-13 2009-12-30 Isis Innovation Method of treatment and screening method
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
WO2011105891A1 (en) 2010-02-23 2011-09-01 Stichting Katholieke Universiteit, More Particularly The Radboud University Nijmegen Medical Centre Combination vaccine for streptococcus
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
HUE045845T2 (hu) 2010-08-17 2021-12-28 Ambrx Inc Módosított relaxin polipeptidek és felhasználásuk
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
DK2707391T3 (en) 2011-05-13 2018-02-05 Gamamabs Pharma ANTIBODIES AGAINST HER3
CN108373502B (zh) 2011-05-20 2022-03-22 H.伦德贝克公司 抗cgrp组合物及其用途
CN103957935B (zh) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
KR102098546B1 (ko) 2011-05-20 2020-04-07 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
CN103747803B (zh) 2011-06-22 2016-10-12 国家医疗保健研究所 抗axl抗体及其用途
EP2723376B1 (en) 2011-06-22 2018-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
ES2692519T3 (es) 2011-07-01 2018-12-04 Novartis Ag Método para tratar trastornos metabólicos
US20140148390A1 (en) 2011-07-08 2014-05-29 Bayer Intellectual Property Gmbh Fusion proteins releasing relaxin and uses thereof
US20140187744A1 (en) * 2011-08-10 2014-07-03 Nipro Corporation Bilirubin Excretion Enhancer
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
BR112014018679A2 (pt) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As variantes de albumina
WO2013170636A1 (zh) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
WO2014012082A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
SI2953969T1 (sl) 2013-02-08 2020-01-31 Novartis Ag Protitelesa proti-IL-17A in njihova uporaba v zdravljenju avtoimunskih in vnetnih motenj
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
MX2016000220A (es) 2013-07-03 2016-08-18 Alder Biopharmaceuticals Inc Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
CN105960414A (zh) 2013-08-14 2016-09-21 诺华股份有限公司 治疗散发性包涵体肌炎的方法
CN105849125B (zh) 2013-11-07 2020-05-15 国家医疗保健研究所 神经调节蛋白变构抗her3抗体
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
US11376333B2 (en) * 2013-12-23 2022-07-05 Covalab mTG substrates for covalent conjugation of compounds
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
EP3161001A2 (en) 2014-06-25 2017-05-03 Novartis AG Antibodies specific for il-17a fused to hyaluronan binding peptide tags
EP3786182A1 (en) 2014-11-19 2021-03-03 Axon Neuroscience SE Humanized tau antibodies in alzheimer's disease
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
EP3835319A1 (en) 2014-12-19 2021-06-16 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
NL2014148B1 (en) 2015-01-16 2017-01-05 Univ Erasmus Med Ct Rotterdam Combination vaccine for camelids.
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
JP6995627B2 (ja) 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
WO2016188911A1 (en) 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
LT3368571T (lt) 2015-10-30 2023-02-10 The Regents Of The University Of California Į transformuojantį augimo faktorių beta atsaką sukuriantys polipeptidai ir jų panaudojimo būdai
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
KR102640157B1 (ko) 2016-03-22 2024-02-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 인간화 항-클라우딘-1 항체 및 이의 용도
US10202435B2 (en) 2016-04-15 2019-02-12 Alder Biopharmaceuticals, Inc. Anti-PACAP antibodies and uses thereof
BR112019001693A2 (pt) 2016-07-29 2019-07-02 Ct Hospitalier Universitaire Toulouse anticorpos direcionados a macrófagos associados a tumores e seus usos
CA3049114A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Antibody fragments for the treatment of biofilm-related disorders
CA3049105A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Dnabii vaccines and antibodies with enhanced activity
WO2018158398A1 (en) 2017-03-02 2018-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
AU2018240117A1 (en) 2017-03-24 2019-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for preventing and treating heart disease
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CN110785433A (zh) 2017-06-28 2020-02-11 诺华股份有限公司 预防和治疗尿失禁的方法
WO2019102435A1 (en) 2017-11-27 2019-05-31 Euro-Celtique S.A. Humanized antibodies targeting human tissue factor
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
US20220047701A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
JP2022512580A (ja) 2018-10-05 2022-02-07 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 細菌バイオフィルムの酵素的破壊のための組成物および方法
EP3914282A1 (en) 2019-01-25 2021-12-01 Ospedale San Raffaele S.r.l. Inhibitor of dux4 and uses thereof
US20220177558A1 (en) 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
BR112021024938A2 (pt) 2019-06-12 2022-01-25 Novartis Ag Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
AU2020311897A1 (en) 2019-07-08 2022-02-03 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
US20220324962A1 (en) 2019-09-27 2022-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance antibodies and uses thereof
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
US20210147525A1 (en) 2019-10-18 2021-05-20 The Regents Of The University Of California Methods and compositions for treating pathogenic blood vessel disorders
WO2021116119A1 (en) 2019-12-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
BR112022013468A2 (pt) 2020-01-10 2022-09-13 Inst Nat Sante Rech Med Proteínas rspo1 e seu uso
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
EP4149558A1 (en) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
EP4153636A1 (en) 2020-06-29 2023-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-protein s single-domain antibodies and polypeptides comprising thereof
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
JP2023535884A (ja) 2021-06-22 2023-08-22 ノバルティス アーゲー 化膿性汗腺炎の処置における使用のための二特異性抗体
IL310154A (en) 2021-07-15 2024-03-01 Diogenx Recombinant variants of R-SPONDIN proteins
WO2023026245A1 (en) 2021-08-27 2023-03-02 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies
WO2023170247A1 (en) 2022-03-11 2023-09-14 Mablink Bioscience Antibody-drug conjugates and their uses
WO2023187657A1 (en) 2022-03-30 2023-10-05 Novartis Ag Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL66614A (en) * 1981-08-28 1985-09-29 Genentech Inc Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
EP0091527A3 (en) * 1981-12-14 1984-07-25 The President And Fellows Of Harvard College Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
JPS6041487A (ja) * 1983-04-25 1985-03-05 ジエネンテツク・インコ−ポレイテツド 酵母発現系でのアルフア因子配列の使用
JPS6087792A (ja) * 1983-09-23 1985-05-17 ジェネックス・コーポレイション 雑種制御領域
GB8510219D0 (en) * 1985-04-22 1985-05-30 Bass Plc Isolation of fermentation products
EP0206733A1 (en) * 1985-06-17 1986-12-30 Genex Corporation Cloned human serum albumin gene
GB8615701D0 (en) * 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
GB8620926D0 (en) * 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter

Also Published As

Publication number Publication date
IE883280L (en) 1989-04-30
DE3876401T2 (de) 1993-04-22
GR3007162T3 (ko) 1993-07-30
EP0322094B1 (en) 1992-12-02
DE3876401D1 (de) 1993-01-14
DK175046B1 (da) 2004-05-10
HU209145B (en) 1994-03-28
FI101381B (fi) 1998-06-15
IE61050B1 (en) 1994-09-21
CA1341298C (en) 2001-09-25
ES2053758T3 (es) 1994-08-01
US5380712A (en) 1995-01-10
FI884993A0 (fi) 1988-10-28
EP0322094A1 (en) 1989-06-28
ATE82858T1 (de) 1992-12-15
JPH02194A (ja) 1990-01-05
AU619768B2 (en) 1992-02-06
DK600688D0 (da) 1988-10-28
KR0153516B1 (ko) 1998-10-15
IL88223A0 (en) 1989-06-30
GB8725529D0 (en) 1987-12-02
DK600688A (da) 1989-06-21
AU2404688A (en) 1989-05-18
FI101381B1 (fi) 1998-06-15
FI884993A (fi) 1989-05-01
IL88223A (en) 1994-10-07
HUT47977A (en) 1989-04-28
ZA888118B (en) 1989-07-26

Similar Documents

Publication Publication Date Title
KR890006668A (ko) 폴리펩티드
US5780594A (en) Biologically active protein fragments containing specific binding regions of serum albumin or related proteins
Bietlot et al. Facile preparation and characterization of the toxin from Bacillus thuringiensis var. kurstaki
KR920701451A (ko) 인체혈청알부민의 n-말단 단편을 함유하는 융합 단백질
ATE208816T1 (de) Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5
DE3588249D1 (de) Methode zur Herstellung von menschlichen Wachstumshormonen
Keller et al. Abalone (Haliotis tuberculata) hemocyanin type 1 (HtH1) Organization of the≈ 400 kDa subunit, and amino acid sequence of its functional units f, g and h
DE69627150T2 (de) Verfahren zur herstellung von gegen e.coli bakterien der familie cs4-cfa/1 gerichteten antikörpern
ATE208815T1 (de) Genetisches igfbp-5 rodierendes material
DE69030920D1 (de) Verfahren zur herstellung von pai-2
Guy et al. The Structure of the Bovine Pancreatic Secretory Trypsin Inhibitor—Kazal's Inhibitor: III. DETERMINATION OF THE DISULFIDE BONDS AND PROTEOLYSIS BY THERMOLYSIN
ATE253639T1 (de) Verfahren zur herstellung von peptiden
DE69131979T2 (de) Genetisches igfbp-4 rodierendes material
Butler et al. Homologous regions of collagen α1 (I) and α1 (II) chains: Apparent clustering of variable and invariant amino acid residues
DE69233155D1 (de) Insulinartigen wachstumsfaktor bindendes protein
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
KR930000684A (ko) 클로닝된 글루탐산 탈탄산효소
Kumar et al. Acetylcholinesterase from a non-membrane source (Bungarus fasciatus venom)
WO2001036476A3 (en) Ing2, an iaps associated cell cycle protein, compositions and methods of use
WO2001036474A3 (en) Srik a novel cell cycle protein associated with rip3
WO2001029072A3 (en) P15paf cell cycle proteins associated with pcna, compositions and methods of use
WO2000063370A3 (en) Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes
KR890002399A (ko) 하이브리드 인터페론 및 재조합 dna기술을 이용한 그의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120620

Year of fee payment: 15

EXPY Expiration of term